Where Pear Therapeutics Stands With Analysts
Within the last quarter, Pear Therapeutics (NASDAQ:PEAR) has observed the following analyst ratings:
BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $11
BTIG analyst Marie Thibault maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $12 to $11.
70 Stocks Moving In Monday’s Mid-Day Session
Gainers
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
91 Biggest Movers From Friday
Gainers
RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
95 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 100.4% to close at $4.75 on Monday after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.
Mid-Afternoon Market Update: Dow Turns Lower; DiDi Global Shares Surge
U.S. stocks pared gains, with the Dow Jones turning lower toward the end of trading on Monday.
Mid-Day Market Update: Nasdaq Rises 1%; Praxis Precision Medicines Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Monday.
52 Stocks Moving In Monday’s Mid-Day Session
Gainers
DiDi Global Inc. (NYSE: DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users.